Abstract
Medication treatment strategies for Crohn’s disease (CD) include step-up (SU) therapy, which initiates with oral anti-inflammatory agents, and top-down (TD) therapy, which initiates with biologics or immunomodulators. The real-world utilization and short-term medical costs associated with these treatment strategies are not well described. This research examined the prevalence of TD therapy use over time and first-year direct medical expenditures among patients initiating CD medication treatment with SU as compared with TD therapy in a real-world setting.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
